Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31599571 | 1.00 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DGABRA1 | |
| SCHEMBL8548467 | 1.00 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DGABRA1 | |
| SCHEMBL11753040 | 0.88 | SMN1; SMN2 (0.48) | PDE4APDE4BPDE4CPDE4DGABRA1 | |
| SCHEMBL625933 | 0.80 | GABRA1 (0.53) | PDE4APDE4BPDE4CPDE4DGABRA1 | |
| SCHEMBL625934 | 0.80 | GABRA1 (0.53) | PDE4APDE4BPDE4CPDE4DGABRA1 | |
| SCHEMBL9644205 | 0.80 | GABRA1 (0.42) | PDE4APDE4BPDE4CPDE4DGABRA1 | |
| SCHEMBL9645499 | 0.80 | GABRA1 (0.42) | PDE4APDE4BPDE4CPDE4DGABRA1 | |
| SCHEMBL625935 | 0.80 | GABRA1 (0.53) | PDE4APDE4BPDE4CPDE4DGABRA1 | |
| SCHEMBL25342763 | 0.78 | GABRA1 (0.58) | PDE4APDE4BPDE4CPDE4DGABRA1 | |
| SCHEMBL11761840 | 0.78 | GABRA1 (0.58) | PDE4APDE4BPDE4CPDE4DGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| EP-4605388-A1 | <SUP2/>? <SUB2/>?3?2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CXCR1 | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | disclosed |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024083933-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX 3CR1 | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | WO | disclosed |
| US-11013700-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2020-04-30 | — | — | US | disclosed |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| WO-1996012697-A9 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMA INC (US) | 2000-08-24 | — | — | WO | disclosed |
| EP-0702003-B1 | Process for preparing 2-halogenpyridinaldehydes | BAYER AG (DE) | 1998-06-17 | — | — | EP | disclosed |
| US-5708180-A | CYCLIZATION OF UNSATURATED NITRILE, AMIDE OR OXIME | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-13 | — | — | US | disclosed |
| EP-0787122-A2 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012697-A2 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0702003-A2 | Process for preparing 2-halogenpyridinaldehydes and new 2-halogenpyridinaldehydes | BAYER AG (DE) | 1996-03-20 | — | — | EP | disclosed |
| US-4994569-A | Cholecystokinin antagonists | RHONE-POULENC SANTE (FR) | 1991-02-19 | — | — | US | disclosed |
| EP-0020950-B1 | PROCESS FOR THE PREPARATION OF ALPHA, BETA-UNSATURATED NITRILES FROM ALDEHYDES AND FORMAMIDE | BASF Aktiengesellschaft (DE) | 1982-05-12 | — | — | EP | disclosed |
| US-4315869-A | Preparation of α,β-unsaturated nitriles | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
| EP-0020950-A1 | Process for the preparation of alpha, beta-unsaturated nitriles from aldehydes and formamide | BASF Aktiengesellschaft (DE) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | PDE4A 287/4885PDE4B 336/4885PDE4C 543/4885 |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | PDE4A 1668/4885PDE4B 1613/4885PDE4C 2069/4885 |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | PDE4A 253/4885PDE4B 297/4885PDE4C 477/4885 |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | PDE4A 1668/4885PDE4B 1613/4885PDE4C 2069/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | PDE4A 1668/4885PDE4B 1613/4885PDE4C 2069/4885 |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | PDE4A 253/4885PDE4B 297/4885PDE4C 477/4885 |
| US-11013700-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | PDE4A 287/4885PDE4B 336/4885PDE4C 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.